Daylight savings time is back, so spring and warm weather are not far off!
Quickening the Pace of Drug Discovery with AI
“The integration of our industry-leading ADMET Predictor and GastroPlus® mechanistic PBPK simulations into the initial generative chemical design process is what sets us apart from other machine learning drug design companies,” says AIDD Principal Scientist and former City of Hope Professor Jeremy Jones. “Our platform offers everything a medicinal chemist would want, at incredible speed.”
Best Company for Women Award
Simulations Plus is excited to announce that we are the recipients of a Comparably Award for “Best Company for Women” in 2022.
What is QST/QSP Modeling?
With more than 20 years of industry experience, Chief Science Officer of DILIsym Services, Scott Q. Siler describes it this way, “think of modeling like photography.”
October 2022 GastroPlus Newsletter
Breaking News! The new version of GP (version 9.8.3) is now available for download.
August 2022 GastroPlus Newsletter
As the summer season heats up here in New England, we invite you all to join us in honoring 2022 World Lung Cancer Day.
August 2022 News/Events
An estimated 236,740 people in the U.S. will be diagnosed with lung cancer in 2022. That’s 649 people each day, 27 people each hour, and one person every 2½ minutes.
FDA’s Project Optimus Initiative for Oncology Drug Development
Oncology drugs have historically followed the dosing strategy that “more is better” until the maximum tolerated dose (MTD) is reached.
An update on the comparison of lixivaptan’s liver safety profile
An update from Dr. Paul B. Watkins on the comparison of lixivaptan’s liver safety profile